Intellia Therapeutics Files 8-K

Ticker: NTLA · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1652130

Sentiment: neutral

Topics: corporate-action, financial-reporting, sec-filing

Related Tickers: NTLA

TL;DR

Intellia Therapeutics filed an 8-K on 6/12/24 covering shareholder votes and financials.

AI Summary

Intellia Therapeutics, Inc. filed an 8-K on June 12, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing details the company's corporate structure and operational information as of the reporting date.

Why It Matters

This filing provides an update on corporate actions and financial reporting for Intellia Therapeutics, Inc., which is relevant for investors tracking the company's governance and financial health.

Risk Assessment

Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating new risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Intellia Therapeutics, Inc.?

The primary purpose is to report on matters submitted to a vote of security holders and to provide financial statements and exhibits, as of June 12, 2024.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is June 12, 2024.

In which state is Intellia Therapeutics, Inc. incorporated?

Intellia Therapeutics, Inc. is incorporated in Delaware.

What is the address of Intellia Therapeutics, Inc.'s principal executive offices?

The principal executive offices are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.

What is the SEC file number for Intellia Therapeutics, Inc.?

The SEC file number for Intellia Therapeutics, Inc. is 001-37766.

Filing Stats: 911 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2024-06-13 16:59:57

Key Financial Figures

Filing Documents

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 12, 2024, Intellia Therapeutics, Inc. (the "Company") filed a Certificate of Second Amendment (the "Amendment") to the Company's Second Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of Delaware to limit the liability of certain officers of the Company as permitted by recent amendments to the Delaware General Corporation Law. The Amendment was approved by the holders of a majority of the outstanding shares of common stock of the Company at its Annual Meeting of Stockholders (the "Annual Meeting"), as described in Item 5.07 below. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is filed with this report as Exhibit 3.1 and is incorporated herein by reference.

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 12, 2024, the Company held its Annual Meeting to consider and vote on the four proposals set forth below, each of which is described in detail in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024. The following is a summary of the matters voted on at the Annual Meeting. a) The stockholders of the Company elected each of Fred Cohen, M.D., D.Phil., and Frank Verwiel, M.D., as a class II director, for a three-year term ending at the annual meeting of stockholders to be held in 2027 and until his successor has been duly elected and qualified or until his earlier resignation or removal. The results of the stockholders' vote with respect to the election of the class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Fred Cohen, M.D., D.Phil. 65,390,554 6,655,846 11,843,099 Frank Verwiel, M.D. 55,820,159 16,226,241 11,843,099 b) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders' vote with respect to such ratification were as follows: Votes For Votes Against Abstain Broker Non-Votes 83,483,463 256,699 149,337 0 c) The stockholders of the Company approved, on an advisory basis, the compensation of the named executive officers. The results of the stockholders' vote with respect to the approval of the compensation of the named executive officers were as follows: Votes For Votes Against Abstain Broker Non-Votes 70,436,308 1,525,957 84,135 11,843,099 d) The stockholders of the Company approved and adopted a second amendment to the Company's Second Amended and Restated Certificate of Incorporation, as amended, to limit the liability of certain officers of

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1* Second Amendment to the Second Amended and Restated Certificate of Incorporation of the Registrant dated June 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: June 13, 2024 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing